Chemical formula: C₁₅H₁₄F₃N₃O₄S₂ Molecular mass: 421.415 g/mol PubChem compound: 2315
Bendroflumethiazide interacts in the following cases:
Bendroflumethiazide inhibits the tubular elimination of lithium, resulting in an elevated plasma lithium concentration and risk of toxicity. Plasma lithium concentrations must be monitored when these drugs are given concurrently. 1
Bendrofluemthiazide is best avoided for the management of oedema of pregnancy or hypertension in pregnancy as it crosses the placenta and their use may be associated with hypokalaemia, increased blood viscosity and reduced placental perfusion.
There is inadequate evidence of safety in human pregnancy. Foetal bone marrow depression and thrombocytopenia as well neonatal jaundice have been reported.
As diuretics pass into breast milk and bendroflumethiazide can suppress lactation, its use should be avoided in mothers who wish to breast feed.
Dizziness, drowsiness, postural hypotension and mental confusion may occur. This may impair ability to drive or operate machinery
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
